Latest News and Press Releases

First patient in SXTP’s relapsing babesiosis study tested negative post-tafenoquine; FDA Breakthrough request filed, Type B meeting planned 2026.

60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.

60 Degrees Pharma (Nasdaq: SXTP) CEO Dr. Geoff Dow to present at HCW Conference Tuesday, Sept 9, 3:30 PM ET. Live webcast link available.

60 Degrees Pharma CEO Dr. Geoff Dow will present Sept 10 at HCW 27th Global Investment Conference; webcast and replay available on company’s investor site.

60 Degrees Pharma selects Mount Sinai as central site for Phase II tafenoquine trial in chronic babesiosis; enrollment starts Q4 2025, data 2026.

60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.

60 Degrees and Tulane to study tafenoquine against Lyme and Bartonella bacteria, part of the “3Bs” common in tick-borne illness co-infections.

60 Degrees closes $5M public offering with up to $5M more from short-term warrants; funds support working capital and infectious disease R&D.

60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.

60 Degrees sets human babesiosis TAM for ARAKODA at $245M annually, $1.1B total through 2035; NDA planned for 2026 pending trial data.